Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.

Clostridioides Difficile Infection Clinical Trials

5 recruiting trials for Clostridioides Difficile Infection. Eligibility criteria explained in plain English.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.
5
Total Trials
5
Recruiting Now
1
Phase 3 Trials
5
Sponsors

Recruiting Trials

RECRUITINGPhase 2 / Phase 3NCT05330182

LMN-201 for Prevention of C. Difficile Infection Recurrence

This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving...

Sponsor: Lumen Bioscience, Inc.Enrolling: 37516 locations
RECRUITINGPhase 2 / Phase 3NCT06979609

Secondary Prevention of Clostridioides Difficile Using Vancomycin

Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor...

Sponsor: McGill University Health Centre/Research Institute of the McGill University Health CentreEnrolling: 3001 location
RECRUITINGPhase 2NCT07285213

Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody

The purpose of this study is to evaluate the efficacy and safety of AZD5148 for prevention of recurrence of Clostridioides difficile infection in Individuals 18 years of age and...

Sponsor: AstraZenecaEnrolling: 23020 locations
RECRUITINGPhase 3NCT06237452

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

The overall objective of the RESTORATiVE303 study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive...

Sponsor: Vedanta Biosciences, Inc.Enrolling: 85220 locations
RECRUITINGPhase 2NCT04305769

Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)

This is a randomized, double-blind, placebo-controlled trial to determine the optimal dose and safety of oral alanyl-glutamine between 4, 24, and 44 g doses administered for 10...

Sponsor: University of VirginiaEnrolling: 2602 locations